Effects of Fractionated Stereotactic Radiotherapy for Primary Hepatocellular Carcinoma.
- Author:
Byeong Ock CHOI
1
;
Ki Mun KANG
;
Hong Seok JANG
;
Sang Wook LEE
;
Young Nam KANG
;
Gyu Young CHAI
;
Ihl Bhong CHOI
Author Information
1. Department of Radiation Oncology, The Catholic University of Korea College of Medicine, Seoul, Korea.
- Publication Type:Clinical Trial ; Original Article
- Keywords:
Hepatocellular carcinoma;
Fractionated stereotactic radiotherapy
- MeSH:
Carcinoma, Hepatocellular*;
Disease-Free Survival;
Dyspepsia;
Follow-Up Studies;
Humans;
Liver;
Radiotherapy*;
Retrospective Studies;
Survival Rate
- From:The Journal of the Korean Society for Therapeutic Radiology and Oncology
2005;23(2):92-97
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Reports on the outcome of curative radiotherapy for the primary hepatocellular carcinoma (HCC) are rarely encountered in the literature. In this study, we report our experience of a clinical trial where fractionated stereotactic radiotherapy (SRT) was used in treating a primary HCC. MATERIALS AND METHODS: A retrospective analysis was performed on 20 patients who had been histologically diagnosed as HCC and treated by fractionated SRT. The long diameter of tumor measured by CT was 2~6.5 cm (average: 3.8 cm). A single dose of radiation used in fractionated SRT was 5 or 10 Gy; each dose was prescribed based on the planning target volume and normalized to 85~99% isocenter dose. Patients were treated 3~5 times per week for 2 weeks, with each receiving a total dose of 50 Gy (the median dose: 50 Gy). The follow up period was 3~55 months (the median follow up period: 23 months). RESULTS: The response rate was 60% (12 patients), with 4 patients showing complete response (20%), 8 patients showing partial response (40%), and 8 patients showing stable disease (40%). The 1-year and 2-year survival rates were 70.0% and 43.1%, respectively, and the median survival time was 20 months. The 1-year and 2-year disease free survival rates were 65% and 32.5%, respectively, and the median disease-free survival rate was 19 months. Some acute complications of the treatment were noted as follows: dyspepsia in 12 patients (60%), nausea/emesis in 8 patients (40%), and transient liver function impairment in 6 patients (30%). However, there was no treatment related death. CONCLUSION: The study indicates that fractionated SRT is a relatively safe and effective method for treating primary HCC. Thus, fractionated SRT may be suggested as a local treatment for HCC of small lesion and containing a single lesion, when the patients are inoperable or operation is refused by the patients. We thought that fractionated SRT is a challenging treatment modality for the HCC.
